| 1.68 -0.04 (-2.33%) | 12-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.45 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.64 |
|||
| Supports | First : | 1.61 | Second : | 1.5 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.64  |
| MA(100) : | 1.73 |
MA(250) : | 2.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 68.5 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 3.2 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DOMH ] has closed below upper band by 34.4%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.78 - 1.79 | 1.79 - 1.8 |
| Low: | 1.66 - 1.67 | 1.67 - 1.68 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Thu, 05 Dec 2024
Despite Recent Gains, Dominari Holdings Insiders Are Still Down US$90k - Simply Wall St
Sun, 10 Nov 2024
Dominari Holdings Third Quarter 2024 Earnings: US$0.67 loss per share (vs US$0.66 loss in 3Q 2023) - Yahoo Finance
Fri, 08 Nov 2024
Dominari Holdings Inc. (DOMH) Quarterly 10-Q Report - Quartzy
Sat, 23 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN
Fri, 15 Mar 2024
Dominari Securities Appoints 30 Year Financial Industry Expert to Manage Operations and Compliance - PR Newswire
Tue, 12 Mar 2024
Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 35.4 (%) |
| Held by Institutions | 7.3 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -3.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.09 |
| Profit Margin | -180.3 % |
| Operating Margin | -79.1 % |
| Return on Assets (ttm) | -16.8 % |
| Return on Equity (ttm) | -47 % |
| Qtrly Rev. Growth | 319.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2 |
| EBITDA (p.s.) | -2.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0.83 |
| Price to Cash Flow | -0.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|